Respiratorius US patent

Patent approval for Respiratorius after complicated process

It has been a long and arduous process, but the long-awaited announcement is finally here. The US Patent and Trademark Office has approved Respiratorius’...
Åsa Magnusson

Lipum strengthens the board with commercial expertise

Lipum has chosen to strengthen the Board of Directors with Åsa Magnusson, who has more than 30 years of experience in the pharmaceutical industry...
Arcede liquidated

Arcede Pharma heading towards liquidation

This spring, Arcede Pharma has worked hard to find a financing solution for the continued work on RCD405, but has not succeeded. Consequently the...
SynAct

SynAct Pharma moves forward with filing process

Following previous studies in rheumatoid arthritis, SynAct Pharma knows much more about the possibilies and requirements for assessing resomelagon’s effect. The company is now...
Alligator Fas II-data

“Unprecedented” phase II data for Alligator in pancreatic cancer

Alligator Bioscience continues to post convincing phase II data with cancer immunotherapy mitazalimab in pancreatic cancer, providing further evidence of the candidate’s potential. Adding...

Spermosens: helping couples succeed in babymaking 

As infertility reaches an alarming rate, in vitro fertilisation is seen as a beacon of hope. Despite its successes, IVF too often leads to...
BioInvent immunotherapy 2.0

Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”

BioInvent recently announced promising clinical data for its lead cancer immunotherapy candidates, BI-1808 and BI-1206. The company hosted a Key Opinion Leader webinar to...
Annexin

Annexin comments on acquisition and focus on ANXV in ophthalmology

Merck recently announced that they are acquiring the biotech company EyeBio for up to 3 billion USD, thereby strengthening its presence in ophthalmology. EyeBio's...
Aqilion and Merck end collaboration

Aqilion and Merck sever ties

Aqilion announced the termination of the licensing and collaboration agreement with Merck for the joint development of the TAK1 programme taking aim at chronic inflammation. The decision follows data...
Oncoinvent

Fast Track designation facilitates development of Oncoinvent’s Radspherin

The FDA has granted Fast Track to Oncoinvent for its radiopharmaceutical Radspherin as a treatment for peritoneal metastases originating from ovarian cancer. This designation...